Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.97 USD
Change Today +0.38 / 3.59%
Volume 3.9K
ALDX On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

aldeyra therapeutics inc (ALDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/28/15 - $13.50
52 Week Low
08/4/14 - $3.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aldeyra therapeutics inc (ALDX) Related Businessweek News

No Related Businessweek News Found

aldeyra therapeutics inc (ALDX) Details

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the research and development of products for the treatment of immune-mediated, inflammatory, orphan, and other diseases in the United States. It is involved in the development of NS2, an eye drop formulation product candidate designed to trap and allow for the disposal of free aldehydes, which has completed Phase I clinical trial; and for the treatment of Sjögren-Larsson Syndrome and noninfectious anterior uveitis. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.

6 Employees
Last Reported Date: 03/23/15
Founded in 2004

aldeyra therapeutics inc (ALDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $70.8K
Chief Operating Officer
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

aldeyra therapeutics inc (ALDX) Key Developments

Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial

Aldeyra Therapeutics, Inc. announced that it has enrolled the first patient in its Phase II clinical trial of NS2 for the treatment of noninfectious anterior uveitis. The study is being conducted at top U.S. anterior uveitis clinical trial sites, and led by Dr. Stephen Foster, a recognized clinical expert in ocular inflammation.

Aldeyra Therapeutics Announces First Patient Enrolled in Sjogren-Larsson Syndrome Phase II Clinical Trial

Aldeyra Therapeutics, Inc. announced that it has enrolled the first patient in its Phase II clinical trial of NS2 for the treatment of Sjogren-Larsson Syndrome (SLS). The trial is being held at the University of Nebraska University Medical Center, the leading treatment center in the United States for SLS.

Aldeyra Therapeutics, Inc. Announces Earnings Results for the Full Year Ended December 31, 2014

Aldeyra Therapeutics, Inc. announced earnings results for the full year ended December 31, 2014. For the year, the company reported loss from operations of $7,270,590 against $3,676,407 a year ago. Net loss attributable to common stockholders was $9,573,911 against net income attributable to common stockholders of $1,109,910 a year ago. Diluted loss per share was $3.09 against $17.61 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALDX:US $10.97 USD +0.38

ALDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALDX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALDEYRA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at